PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSomatostatin
Somatostatin
Somatostatin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CB: Somatostatin and analogues
— H01CB01: Somatostatin
HCPCS
No data
Clinical
Clinical Trials
311 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.824391432189
AcromegalyD000172——271091744
Portal hypertensionD006975EFO_0000666K76.62121510
Liver cirrhosisD008103EFO_0001422K74.011—168
MedulloblastomaD008527——26—1—7
MeningiomaD008579EFO_0003098D32.924—117
ParagangliomaD010235——25—117
Esophageal and gastric varicesD004932EFO_0009545I85111136
NeoplasmsD009369—C8012—115
Pituitary neoplasmsD010911———312—5
Show 14 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carcinoid tumorD002276—D3A.004112—116
Autosomal dominant polycystic kidneyD016891EFO_1001496Q61.2—36——7
Liver neoplasmsD008113EFO_1001513C22.0124—16
Hepatocellular carcinomaD006528—C22.0121——3
GliomaD005910EFO_0000520—121——2
Carcinoid heart diseaseD002275EFO_1001769——11——2
AnemiaD000740HP_0001903D64.9—11——2
Gastrointestinal hemorrhageD006471HP_0002239K92.2—11——2
Thymus neoplasmsD013953—C37—11——2
Pancreatic diseasesD010182—K86.9—11—12
Show 13 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine carcinomaD018278——39——313
NeuroblastomaD009447EFO_0000621—46———8
Pancreatic neoplasmsD010190EFO_0003860C2522——58
PheochromocytomaD010673——34———6
Central nervous system neoplasmsD016543——41———4
Lung neoplasmsD008175HP_0100526C34.9031———4
Type 1 diabetes mellitusD003922EFO_0001359E1011——24
Breast neoplasmsD001943EFO_0003869C5021———3
Small cell lung carcinomaD055752——23———3
Gastrointestinal neoplasmsD005770—C26.9—2——13
Show 30 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoglycemiaD007003HP_0001943E16.21———45
Insulin resistanceD007333HP_0000855E88.8191———34
Islet cell adenomaD007516EFO_0007331D13.73————3
Type 2 diabetes mellitusD003924EFO_0001360E112———13
LymphomaD008223—C85.91———12
Paraneoplastic syndromesD010257——2————2
AgingD000375GO_0007568R41.811———12
Colorectal neoplasmsD015179——1————1
Colonic neoplasmsD003110—C181————1
SarcomaD012509——1————1
Show 10 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81————44
Esophageal neoplasmsD004938—C15————44
MalnutritionD044342EFO_0008572E40-E46————22
Weight lossD015431HP_0001824—————22
Duodenal neoplasmsD004379——————22
ObesityD009765EFO_0001073E66.9————22
Laron syndromeD046150Orphanet_633E34.321————22
Nasopharyngeal neoplasmsD009303——————22
Postoperative painD010149—G89.18————11
Arm injuriesD001134——————11
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSomatostatin
INNsomatostatin
Description
SOMATOSTATIN
Classification
Protein
Drug classgrowth hormone derivatives; enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O
Identifiers
PDB—
CAS-ID38916-34-6
RxCUI—
ChEMBL IDCHEMBL1823872
ChEBI ID64628
PubChem CID—
DrugBank—
UNII ID6E20216Q0L (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 55,040 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
75 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use